CONTACT
+91 80 2808 2808
info@biocon.com

Press Releases

Biocon  /  News – Posts  /  Press Releases

Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States

  • Posted by: BIOCON

Advancing Bone Health: European Commission Approves Biocon Biologics’ Denosumab Biosimilars

  • Posted by: BIOCON

Biocon Biologics Expands Insulin Access in Malaysia

  • Posted by: BIOCON

Biocon Biologics Receives Health Canada Approval for Yesafili™ (aflibercept); First Global Launch Scheduled for July 2025

  • Posted by: BIOCON

Biocon Biologics Collaborates with National Cancer Society Malaysia

  • Posted by: BIOCON

Biocon Limited Concludes a Rs 4,500 Crore (USD 523 million ) Equity Fundraise through a Qualified Institutions Placement (QIP)

  • Posted by: BIOCON

Biocon Foundation in Partnership with NCBS and BeST Cluster Launches BioWISE Program – to Empower Women in STEM

  • Posted by: BIOCON

Biocon Limited gets approval for diabetes drug Liraglutide in India

  • Posted by: BIOCON

Biocon Q4FY25 Revenue at Rs 4,454 Cr, Up 15%** EBITDA at Rs 1,115 Cr; Up 16%; Net Profit at Rs 344 Cr, Up 153%

  • Posted by: BIOCON

Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives

  • Posted by: BIOCON
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>